Compare Fabrinet (FN) vs HCA Health Inc (HCA) Price & Performance

Fabrinet (FN) trades at $474.19, down 1.78% on the day, with a bearish technical signal despite strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with a $733 price target, though technical indicators show selling pressure with support at $473 and resistance at $484.

FN presents a compelling growth story driven by AI infrastructure demand, with revenue projected to grow from $3.42B to $4.2B in 2026. However, premium valuation metrics (P/E 41.81, P/B 7.57) and technical bearishness create near-term headwinds. The risk-reward favors long-term investors given the company's strategic positioning in optical communications and debt-free balance sheet.

HCA Healthcare (HCA) is trading at $363.60, down 6.95% amid lowered 2026 guidance. The stock shows bearish technical signals but maintains strong fundamentals with consistent revenue growth to $75.6 billion in 2025 and earnings beats in recent quarters. Analyst consensus remains bullish with a $469.40 price target despite recent negative sentiment from payer mix challenges.

The outlook presents a value opportunity given attractive valuation multiples (P/E 13.05, EV/EBITDA 8.48) and dividend yield, though risks include rising uninsured patients and margin compression. Long-term growth drivers include capacity expansion and specialty care investments, but near-term volatility may persist until Q2 earnings clarity.